

**Amendments to the Specification:**

Please replace paragraph [0011] with the following rewritten paragraph:

**[0011]** The invention relates to the formation of Membrane Attack Complex (MAC) [also referred as Terminal Complement Complex (TCC) or C5b-9] on CIC and the applications of measuring complement products including C1q, C3, C4, C5, MAC and its components on CIC as diagnostic markers and reduction in the amount of the MAC on CIC by blocking the formation of MAC on CIC by, for example, administering an inhibitory amount of monoclonal antibodies having specificity for MAC or selectively removing the MAC from the CIC for treatment or prophylaxis of the complement and CIC mediated diseases.